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Abstract 
Background: Patients with atrial fibrillation (AF) have an increased risk of cognitive decline, 
potentially due to clinically unrecognized vascular brain lesions.  
Objectives: To assess the relationships between cognitive function and vascular brain lesions in 
AF patients. 
Methods: Patients with known AF were enrolled in a multicenter study in Switzerland. Brain 
magnetic resonance imaging (MRI) and cognitive testing using the Montreal Cognitive 
Assessment (MoCA) were performed in all participants. Large non-cortical or cortical infarcts 
(LNCCIs), small non-cortical infarcts (SNCIs), microbleeds and white matter lesions (WML) 
were quantified by a central core laboratory. Clinically silent infarcts were defined as infarcts on 
brain MRI in patients without a clinical history of stroke or transient ischemic attack (TIA).  
Results: We included 1737 patients with a mean age of 73±8 years (28% women, 90% on oral 
anticoagulation). On MRI, LNCCIs were found in 387 patients (22%), SNCIs in 368 (21%), 
microbleeds in 372 (22%) and WMLs in 1715 (99%). Clinically silent infarcts among the 1390 
patients without a history of stroke/TIA were found in 201 (LNCCI; 15%) and 245 (SNCI; 18%), 
respectively. The MoCA score was 24.7±3.3 and 25.8±2.9 in those with and without LNCCIs on 
brain MRI (p<0.001). The difference in MoCA score remained similar when only clinically 
silent LNCCIs were considered (24.9±3.1 versus 25.8±2.9, p<0.001). In a multivariable 
regression model including all vascular brain lesion parameters, LNCCI volume was the 
strongest predictor for a reduced MoCA (β=-0.26, 95% confidence interval, -0.40 to -0.13, 
p<0.001). 
Conclusions: AF patients have a high burden of LNCCIs and other brain lesions on systematic 
brain MRI screening, the majority being clinically silent. LNCCIs were associated with worse 
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cognitive function, even among patients with clinically silent infarcts. Our findings raise the 
question of MRI screening in AF patients. 
 
Condensed abstract: 
Patients with atrial fibrillation (AF) have an increased risk of cognitive dysfunction, potentially 
due to clinically unrecognized vascular brain lesions. We performed systematic brain MRIs and 
cognitive testing in 1737 patients. The overall prevalence of cerebral infarcts was 22%. The 
prevalence of silent infarcts in patients without a history of stroke or transient ischemic attack 
was 15%. Cognitive function was significantly worse in those with cerebral infarcts, and this 
difference was similar in those with overt or silent brain infarcts. Thus, AF patients have a high 
burden of silent cerebral infarcts, and these infarcts were associated with worse cognitive 
function. 
Keywords: Atrial fibrillation, Cognitive dysfunction, Silent cerebral infarcts, Microbleeds, 
White matter lesions 
 
Abbreviations 
AF    Atrial fibrillation 
MRI    Magnetic resonance imaging 
SNCI    Small non-cortical infarct 
LNCCI   Large non-cortical infarcts or cortical infarct 
MoCA    Montreal Cognitive Assessment 
TIA    Transient ischemic attack 
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Introduction 
The prevalence of atrial fibrillation (AF) in the general population is increasing rapidly 
(1). Patients with AF are at high risk of adverse events. While the relationships of AF with death, 
stroke and congestive heart failure have been known for many years (2,3), more recent evidence 
suggests that patients with AF also face an increased risk of cognitive dysfunction and dementia 
(4,5). This growing awareness is reflected by a recent publication of an international expert 
consensus paper on this topic (6).  
Meta-analyses suggest that part of the association between AF and dementia is explained 
by the higher stroke risk among AF patients, but the risk of dementia was also increased in AF 
patients without a clinical history of stroke (5). Clinically unrecognized (silent) cerebral infarcts, 
microbleeds or other brain lesions may explain this association, but systematic investigations in 
patients with AF are currently lacking. Microbleeds are of particular interest, as patients with AF 
usually need lifelong oral anticoagulation for stroke prevention (7). Although prior studies did 
not show a consistent trend of more microbleeds among patients using oral anticoagulation, its 
use among patients with a significant burden of microbleeds remains controversial (8-10).  
The aim of the current study was to assess the relationships of clinically known and 
unknown (silent) vascular brain lesions detected on brain magnetic resonance imaging (MRI) 
with cognitive function in a large sample of patients with AF. We focused on large infarcts and 
infarcts involving the brain cortex, which may origin from embolic mechanisms and as such 
represent AF-related sequelae. We also considered imaging markers of cerebral small vessel 
pathology, which share vascular risk factors with AF, including white matter disease, small non-
cortical infarcts and microbleeds (11). Both cerebral small vessel disease and embolic stroke are 
key mechanisms underlying the development of vascular dementia (12).   
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Methods 
Study design and participants 
The Swiss Atrial Fibrillation (Swiss-AF) study is an ongoing prospective cohort study 
that enrolled 2415 patients between 2014 and 2017 across 14 centers in Switzerland. The 
detailed methodology has been described previously (13). Patients were eligible for Swiss-AF if 
they had a history of documented AF and if they were 65 years or older. In addition, we aimed to 
enroll 10-15% of patients aged between 45 and 65 years to assess the effects of AF on 
individuals in the active workforce. We excluded patients with secondary forms of AF and 
patients who were unable to provide informed consent. Patients with an acute illness within the 
last 4 weeks could only be enrolled once the acute episode had resolved.  
Of the 2415 patients enrolled in Swiss-AF, 667 did not have a brain MRI at baseline. The 
main reason for a missing brain MRI was the presence of a cardiac device (n=461; 69%). Other 
reasons included further contraindications to perform an MRI or claustrophobia of the patient. 
An additional 11 patients did not undergo cognitive testing, leaving 1737 participants for the 
present analysis. The local ethics committees approved the study protocol and written informed 
consent was obtained from all participants. 
Clinical measures 
Information on personal characteristics, risk factors, co-morbidities, antithrombotic 
treatment and other factors was obtained through standardized case report forms. Weight and 
height were directly measured and body mass index calculated as weight in kilograms divided by 
height in meters squared. At baseline, three consecutive blood pressure measurements were 
obtained, and the mean of the last two were used in all analyses. We classified AF into 
paroxysmal, persistent and permanent AF according to recommended definitions (7).  
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Brain magnetic resonance imaging 
Brain MRI was acquired on a 1.5 or 3.0 Tesla scanner. The standardized protocol 
included a 3D T1 weighted (T1w) Magnetization Prepared Rapid Gradient Echo (MPRAGE; 
spatial resolution 1.0x1.0x1.0 mm3), a 2D axial Fluid Attenuated Inversion Recovery (FLAIR; 
spatial resolution 1.0x1.0x3.0 mm3), and 2D axial Diffusion weighted imaging (DWI; spatial 
resolution 1.0x1.0x3.0 mm3) sequence with whole brain coverage and without interpolation. In 
addition, either a 2D axial Susceptibility weighted imaging (SWI; spatial resolution 1.0x1.0x3.0 
mm3) or a 2D axial T2* weighted (spatial resolution of 1.0x1.0x3.0 mm3) sequence was applied.  
All brain MRI’s were analyzed centrally in a specialized imaging core laboratory 
(Medical Image Analysis Centre, Basel, Switzerland). MRI’s were analyzed by blinded expert 
raters unaware of personal characteristics or cognitive function. They marked and segmented 
lesions in a standardized fashion using an in-house procedure approved for international clinical 
studies. Board certified neuro-radiologists confirmed all ratings. Small non-cortical infarcts 
(SNCI) were defined as hyperintense lesions on FLAIR ≤20 mm in diameter on axial sections 
and not involving the cortex, consistent with ischemic infarction in the territory of a perforating 
arteriole (located in the white matter, internal or external capsule, deep brain nuclei, thalamus or 
brainstem) (11). We did not further differentiate between small non-cortical infarcts and lacunes 
based on the presence or absence of a central fluid-filled cavity. Large non-cortical infarcts were 
non-cortical infarcts with a diameter >20 mm. Cortical infarcts were defined as hyperintense 
lesions on FLAIR involving the cortex irrespective of their size and whether or not they also 
involved subcortical areas. For the present analysis we differentiated between (A) SNCIs and (B) 
large non-cortical infarcts or cortical infarcts (LNCCIs). Hyperintense white matter lesions were 
graded using the Fazekas scale, and at least moderate disease was defined as a score ≥2 in either 
the periventricular or the deep white matter region (14). Perivascular spaces were identified, 
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differentiated by their tubular morphology and subsequently excluded. FLAIR hyperintense 
lesions not meeting the criteria mentioned above were identified as white matter lesions. 
Microbleeds were identified and counted as nodular, strongly hypointense lesions on either 
T2*w or SWI. T2w volumes of non-cortical and cortical infarcts as well as white matter lesions 
were segmented and quantified semi-automatically using Amira (Mercury Computer Systems 
Inc., Chelmsford, USA). Lesions with a central FLAIR-hypointense core were segmented in total 
without differentiating between hyper- and hypointense lesion areas. 
Cognitive testing 
All study personnel was centrally trained to perform a standardized neurocognitive 
assessment. The Montreal Cognitive Assessment (MoCA) evaluates visuospatial and executive 
functions, confrontation naming, memory, attention, language and abstraction (15). Patients can 
obtain a maximum of 30 points, with higher scores indicating better cognitive function. One 
point was added to the total test score if the patient had 12 years or less of formal education.  
Statistical analysis 
Baseline characteristics were stratified by the presence or absence of a clinical history of 
stroke or transient ischemic attack (TIA) and presented as mean ± standard deviation for 
continuous variables or as counts (percentages) for nominal variables. We compared differences 
across groups with Wilcoxon’s rank-sum tests or Chi-square tests, as appropriate. Silent cerebral 
infarcts were defined as cerebral infarcts (LNCCIs or SNCIs) on brain MRI in patients without a 
history of stroke or TIA. Lesion volumes were indicated as median (interquartile range) given 
their skewed distribution.  
As history of stroke/TIA is a key predictor of lower cognitive function, we repeated all 
main analyses in patients without a history of stroke/TIA. To assess the associations of vascular 
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brain lesion parameters with MoCA score values and to adjust for potential confounders, we 
constructed linear mixed effects regression models in which study center was included as a 
random intercept to account for potential differences across study centers. We first fitted 
univariable models using log-transformed and centered vascular brain lesion parameters (or 
counts for microbleeds) as MoCA score predictors. Separate models were constructed for each 
brain lesion parameter. Univariable models were adjusted for a pre-defined set of covariates, 
including age, sex, body mass index, education level, smoking status, history of hypertension, 
history of diabetes, AF type and use of oral anticoagulation. Finally, we constructed a combined 
multivariable model including all structural brain lesion parameters in a single model. We 
performed two sensitivity analyses, one that additionally adjusted the combined model for a 
history of cardioversion or left atrial ablation, and one adjusting for time since first AF diagnosis. 
Finally, to examine the independence of SNCI and LNCCI, we performed two additional 
analyses in which we excluded patients who had both SNCIs and LNCIs on brain MRI.  
MoCA scores were compared across different strata and subgroups using likelihood ratio 
tests between mixed effects models with and without the stratum as single predictor. In all 
models, we included dummy indicators representing the presence or absence of each vascular 
brain lesion type, in addition to the actual volume or count measurement. Visual model 
diagnostics were performed, and no major violations of model assumptions of homogeneity and 
normally distributed residuals were detected. The microbleed count was truncated at 20, and 
three outliers were given a count of 20 to minimize their influence on the associations. All 
analyses were performed on an available data basis and conducted using R version 3.5.1 (R Core 
Team, 2018); mixed effects models were constructed using the nlme package (16).  
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Results 
Baseline characteristics are shown in Table 1. Mean age was 73±8 years, 28% of 
participants were women, 90% were anticoagulated at the time of study enrollment (54% non-
vitamin K antagonists, 36% vitamin K antagonists), and 18% were on antiplatelet therapy. 
Patients with a history of stroke/TIA were older, had a higher prevalence of hypertension and 
diabetes and they were more often on oral anticoagulation.  
Prevalence and size of vascular brain lesions detected on brain MRI are shown in Table 
2. At least one LNCCI was detected in 22% of participants, with a median volume of 1623 mm3. 
SNCIs were observed in 21% (median volume 63 mm3). The overlap between LNCCI and SNCI 
was small, 80% of patients with SNCIs had no LNCCI, and 75% of patients with LNCCI had no 
SNCI, such that 37% of the study population had either LNCCIs or SNCIs. Microbleeds in 22% 
(median count 1) and white matter lesions in 99% (volume 3918 mm3). The extent of white 
matter lesions was at least moderate in 54% of participants. When patients with a history of 
stroke/TIA were excluded, 201 of 1390 (15%) participants had evidence of a silent LNCCI 
(volume 525 mm3), and 245 (18%) had evidence of a silent SNCI (volume 57 mm3) (Table 2).  
Comparisons of MoCA scores between patients with and without a specific vascular 
brain lesion are shown in Figure 1 and in Table S1. The least square mean MoCA was 24.9 
(95% confidence interval [CI], 24.3 to 25.5) and 25.9 (95% CI, 25.3 to 26.5) among patients with 
and without an LNCCI on brain MRI (p<0.001). The MoCA was 25.0 (95% CI, 24.4 to 25.6) 
versus 25.9 (95% CI, 25.3 to 26.4) in patients with and without an SNCI (p<0.001), and 25.4 
(95% CI, 24.7 to 26.0) versus 25.8 (95% CI, 25.2 to 26.4) in patients with and without 
microbleeds (p=0.07). When patients with a clinical history of stroke or TIA were excluded, the 
MoCA score difference between patients with or without silent LNCCI (25.1 [95% CI, 24.4 to 
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25.7] versus 26.0 [25.4 to 26.5], p<0.001), with or without silent SNCI (25.1 [95% CI, 24.5 to 
25.7] versus 26.0 [95% CI, 25.4 to 26.5], p<0.001), and with or without microbleeds (25.5 [95% 
CI, 24.9 to 26.2] versus 25.9 [95% CI, 25.3 to 26.5], p=0.15) remained of similar magnitude. 
In univariable regression models, LNCCI volume on brain MRI was significantly related 
to MoCA scores, with larger infarct volumes predicting lower MoCA scores (β=-0.28, [95% CI, 
-0.42 to -0.13], p<0.001) (Table 3). A similar finding was observed with white matter lesion 
volume (β=-0.38, [95% CI, -0.49 to -0.28], p<0.001), and presence of at least moderate white 
matter lesions (β=-0.99 [95% CI, -1.27 to -0.72], p<0.001). There was no significant association 
with SNCI volume or microbleed count. In multivariable models, LNCCI count and volume as 
well as presence of at least moderate white matter lesions (β=-0.40 [95% CI, -0.68 to -0.11], 
p=0.007) remained strongly associated with lower MoCA scores (Table 3). Coefficients of all 
covariates included in the multivariable models are presented in Table S2. In a combined 
multivariable model including all vascular brain lesion parameters, LNCCI count and volume 
were the strongest predictors of the MoCA score (Table 3, and Table S3). When we excluded 
patients with a history of stroke/TIA, presence of LNCCI (β=-0.53, [95% Cl, -0.94 to -0.12], 
p=0.012), LNCCI volume (β=-0.18, [95% Cl, -0.39 to 0.02], p=0.072) and presence of at least 
moderate white matter lesions (β=-0.46, [95% CI, -0.77 to -0.16], p=0.003) remained associated 
with the MoCA score (Table 3, and Tables S4 and S5). Sensitivity analyses with models 
including covariates for a baseline history of cardioversion and left atrial ablation, or time since 
first AF diagnosis provided very similar results (Tables S6 to S9). Excluding patients with both 
SNCIs and LNCCIs on brain MRI also provided similar results (Tables S10 and S11).  
Stratified MoCA score results are shown in Figure 2. The overall mean MoCA score was 
25.5±3.1. It was 24.7±3.7 and 25.6±2.9 among patients with and without a clinical history of 
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stroke (p<0.001). MoCA scores also differed across strata of age, AF type, hypertension, 
diabetes, oral anticoagulation, and CHA2DS2-VASc score, but not sex. Patients with permanent 
AF had lower MoCA scores than patients with paroxysmal or persistent AF, a finding that 
persisted in multivariable models (Table S2). The same subgroups were assessed for differences 
in brain lesion parameters (Table S12). Larger LNCCI volumes were observed in patients with 
permanent AF, higher CHA2DS2-VASc scores, and those with a history of stroke, hypertension, 
or diabetes. Oral anticoagulation with either non-vitamin K antagonists or vitamin K antagonists 
was not associated with a higher microbleed count compared to no anticoagulation. Higher 
CHA2DS2-VASc scores were associated with significantly higher infarct and white matter lesion 
volumes, but lower microbleed counts (Table S12).  
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Discussion 
Several important findings emerged from this comprehensive analysis of vascular brain 
lesions and cognitive function in AF patients. First, participants had a substantial burden of 
vascular brain lesions detected on systematic brain MR imaging: 22% and 21% had evidence of 
a previous LNCCI and SNCI, respectively. Second, among patients without a history of 
stroke/TIA, 15% and 18% still had evidence of a previous clinically silent LNCCI and SNCI, 
respectively. Thus, most of the observed lesions were clinically silent. Third, these findings were 
observed in a population with a high prevalence of oral anticoagulation at the time of brain MRI. 
Fourth, patients with an LNCCI had a lower cognitive function than those without LNCCI. The 
magnitude of this difference was similar for patients with silent infarcts, and similar to the effect 
of a previous stroke. Fifth, SNCI volume, white matter lesion volume and microbleed count were 
not independently associated with cognitive function in a combined multivariable model 
including all lesion types. Finally, anticoagulation was not related to a higher microbleed count.  
Comparing the prevalence of brain MRI lesions across studies is difficult, because of 
differences in definitions and technologies. Nevertheless, the infarct prevalence of 37% in our 
study seems to be higher than in  the general population, where the infarct prevalence was 31%. 
In addition, the great majority of these infarcts were small (17). Another study found that the 
presence of clinically silent infarcts on brain MRI approximately doubled the risk of dementia 
and led to a steeper decline in cognitive function (18).  
In order to understand the relationships between AF and cognitive impairment, we 
specifically assessed imaging markers of vascular pathologies known to be associated with 
vascular dementia, which is the most common cause of dementia following Alzheimer’s disease. 
Vascular dementia is a heterogeneous disorder caused by a variety of mechanisms (12), the most 
14/26 
important of which are infarction of the brain cortex (multi-infarct dementia) and cerebral small 
vessel disease. When we corrected the impact of the different lesions types on cognition for each 
other, we found that only LNCCI was significantly associated with a significantly lower  MoCA 
score. The magnitude of the difference was similar when only silent infarcts in patients without a 
history of stroke/TIA were considered. In contrast, none of the imaging markers of small vessel 
disease, including white matter lesions, SNCI and microbleeds, were associated with cognitive 
imparirment in the combined multivariable model. Therefore, silent LNCCIs but not small vessel 
disease may explain the association between AF and dementia in the absence of clinically overt 
strokes (Central illustration) (5).  
While a 1-point MoCA score difference may seem small on an absolute scale, it is similar 
to a 10-year age difference or the presence of hypertension or diabetes (Figure 2). We therefore 
expect such a difference to be relevant from a clinical and societal perspective. As the majority 
of brain infarcts were clinically silent and observed in patients without a history of stroke/TIA, 
our data raise the issue of brain MRI screening in patients with AF. Future studies should 
develop risk scores for AF patients that identify subgroups of AF patients who may benefit from 
brain imaging to better guide antithrombotic treatment in a cost-efficient manner. It is intriguing 
that permanent AF was associated with a lower MoCA score independent of covariates and brain 
lesion volumes (Table S3), suggesting that the arrhythmia itself or associated treatments may 
have a direct effect on cognition. This supports findings from a prior study showing worse 
cognition in AF patients without evidence of brain infarcts on MRI (19).  
Oral anticoagulation effectively prevents stroke in patients with AF (20). Although our 
cross-sectional analysis cannot address the question of whether the cerebral infarcts occurred 
before or after initiation of oral anticoagulation, it nevertheless raises the issue that 
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anticoagulation might not be sufficient to prevent a significant number of silent infarcts, 
especially those caused by mechanisms other than cardiac embolism. A combination of aspirin 
and low-dose rivaroxaban was significantly better than aspirin alone for stroke prevention among 
patients with stable vascular disease but without AF (21). Whether such a treatment strategy may 
also benefit patients with AF is currently unknown. Finally, both history of hypertension and 
diabetes were significantly associated with lower MoCA scores in multivariable analyses, 
suggesting that the high prevalence of cardiovascular risk factors in patients with AF may also 
contribute to the occurrence of overt and silent cerebral lesions.  
Although its detailed histopathological correlates still need to be investigated, 
microbleeds are considered to be small bleedings in the brain (22). Patients with microbleeds 
have an increased risk of stroke and intracranial hemorrhage (23,24). In our study with a high 
prevalence of anticoagulation use, 22% of participants had microbleeds. This prevalence is 
similar to that in elderly individuals from the general population (25), or patients with ischemic 
stroke (26). Anticoagulation use was not associated with a higher microbleed count and 
microbleed count was not associated with cognitive function. This is in agreement with data 
showing that aspirin and apixaban had a similar impact on the incidence of microbleeds (27). 
Currently available data therefore suggest that anticoagulation is safe in most patients with 
microbleeds, although it remains controversial whether there is a subgroup of patients with a 
high microbleed burden who should not be anticoagulated despite their high stroke risk (28,29).  
Strengths of this study include the large sample size of very well-characterized AF 
patients, including the availability of brain MRI and cognitive testing. A potential limitation 
includes the cross-sectional design of this analysis, precluding the assessment of causality or 
directionality of effect. Participants in our study were mostly white and all were enrolled in the 
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compulsory Swiss health insurance system. Whether our data are applicable to other population 
groups or settings remains to be determined. Finally, our study included only AF patients, and it 
is unclear how the prevalence of vascular brain lesions compares with that of other sample 
populations.  
In conclusion, in this large study of well treated AF patients we found a high burden of 
vascular brain lesions on systematic brain MRI screening. Most of these lesions were previously 
unrecognized. Our analyses show that the presence of overt or silent LNCCIs on MRI have a 
similar impact on cognitive function as overt strokes, suggesting that they may explain at least 
part of the increased risk of cognitive dysfunction in this patient population. On the other hand, 
microbleeds were not significantly associated with cognitive function. Finally, the value of 
routine MRI scanning and cognitive function testing for better risk stratification of AF patients 
should be assessed in further studies. 
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Clinical perspectives 
Competency in medical knowledge 1: our study shows that most brain infarcts observed in 
patient with AF are clinically silent. A large number of silent and overt lesions were observed 
despite the fact that 90% of the patients were taking oral anticoagulation at the time of the brain 
MRI.  
Translational outlook 1: Future studies should evaluate whether and which AF patients may 
benefit from brain MRI screening. They should also address the question about the optimal 
antithrombotic treatment to prevent silent infarcts in patients with AF.  
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Figure Legends 
Figure 1. Least square mean MoCA score according to the presence or absence of a specific 
vascular brain abnormality. A) All patients; B) Patients without a history of stroke or transient 
ischemic attack. Least square means were obtained from linear mixed effects models that 
included covariates for the presence versus absence of a specific damage and damage volume 
(count for microbleeds), and study center as random intercept. MoCA: Montreal Cognitive 
Assessment; SNCI: small non-cortical infarcts; LNCCI: large non-cortical or cortical infarcts; 
Faz: Fazekas scale. 
Figure 2. MoCA score across predefined strata. 
Data are mean ± standard deviation. P values represent overall differences across strata and were 
obtained from linear mixed effects models with each strata variable as predictor and study center 
as random intercept. MoCA: Montreal Cognitive Assessment; NOAC: non-vitamin K antagonist; 
VKA: vitamin K antagonist. 
Central Illustration. Potential relationships of overt and silent brain lesions with cognitive 
function in patients with atrial fibrillation. 
Abbreviations: TIA=transient ischemic attack; SNCI=Small Non-cortical Infarcts; 
LNCCI=Large Non-cortical or Cortical Infarcts; WML=White Matter Lesion. 
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Table 1 Baseline characteristics 
Characteristic 
All patients 
(N=1737) 
No history of stroke/TIA 
(N=1390) 
History of stroke/TIA 
(N=347) p-value* 
Age, y 73±8 72±9 75±7 <0.001 
Female sex, No. (%) 477 (28) 369 (27) 108 (31) 0.10 
Body-mass index, kg/m2  27.7±4.8 27.8±4.8 27.3±4.7 0.10 
Blood pressure, mmHg 135±19 / 79±12 135±18 / 79±12 135±19 / 78±12 0.69 / 0.12 
History of hypertension, No. (%) 1197 (69) 939 (68) 258 (74) 0.017 
History of diabetes mellitus, No. (%) 265 (15) 197 (14) 68 (20) 0.015 
Smoking status, No. (%)    0.73 
Current 168 (10) 138 (10) 30 (9)  
Past 871 (50) 697 (50) 174 (50)  
Never 695 (40) 552 (40) 143 (41)  
Education level†, No. (%)    0.43 
Basic 203 (12) 157 (11) 46 (13)  
Middle 850 (49) 677 (49) 173 (50)  
Advanced 684 (39) 556 (40) 128 (37)  
Atrial fibrillation type, No. (%)    0.012 
Paroxysmal 797 (46) 623 (45) 174 (50)  
Persistent 524 (30) 442 (32) 82 (24)  
Permanent 416 (24) 325 (23) 91 (26)  
History of coronary artery disease, No. 
(%) 
462 (27) 363 (26) 99 (29) 0.40 
History of clinical stroke, No. (%) 230 (13) 0 (0) 230 (66) - 
22/26 
History of TIA, No. (%) 159 (9) 0 (0) 159 (46) - 
History of heart failure, No. (%) 376 (22) 295 (21) 81 (23) 0.44 
History of major bleeding, No. (%) 97 (6) 72 (5) 25 (7) 0.18 
CHA2DS2-VASc score 3.3±1.7 2.8±1.4 5.3±1.3 <0.001 
Oral anticoagulation, No. (%) 1560 (90) 1236 (89) 324 (93) 0.019 
Non-vitamin K antagonists 929 (54) 741 (53) 188 (54) 0.82 
Vitamin K antagonists 631 (36) 495 (36) 136 (39) 0.24 
Antiplatelet therapy, No. (%) 309 (18) 237 (17) 72 (21) 0.12 
Data are means ± SD or counts (percentages). TIA: transient ischemic attack. 
* P value compares patient with and without a history of stroke/TIA. P values were obtained from Wilcoxon’s rank-sum tests for continuous 
variables and chi-square tests for categorical variables. 
† Basic education: ≤6 years (less than compulsory education curriculum); middle education: 6 to ≤12 years (high school or similar); 
advanced education: ≥12 years (college or university degree). 
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Table 2 Prevalence of vascular brain lesions detected on brain magnetic resonance imaging 
Characteristic Prevalence Volume, mm3 Counts 
All patients (N=1737)  
Small non-cortical infarcts 368 (21) 63 [30-163] 1 [1-3] 
Large non-cortical or cortical infarcts 387 (22) 1623 [255-7314] 1 [1-2] 
Microbleeds 372 (22) - 1 [1-2] 
White matter lesions 1715 (99) 3918 [1439-9783] 23 [11-41] 
Fazekas scale ≥2 928 (54)   
Patients without a history of stroke or TIA (N=1390)  
Small non-cortical infarcts 245 (18) 57 [30-141] 2 [1-3] 
Large non-cortical or cortical infarcts 201 (15) 525 [162-3396] 1 [1-2] 
Microbleeds 272 (20) - 1 [1-2] 
White matter lesions 1372 (99) 3512 [1323-8669] 21 [10-40] 
Fazekas scale ≥2 694 (50)   
Data are counts (percentages) or median [interquartile range]. TIA: transient ischemic attack. 
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Table 3 Linear mixed effect models assessing the relationships of MoCA score with vascular brain lesion parameters 
 Presence of damage type  Volume/count 
Predictor of interest β coefficient 95% CI p value 
 
β coefficient 95% CI p-value 
All patients        
Small non-cortical infarcts        
Univariable -0.87 (-1.22, -0.53) <0.001  -0.15 (-0.41, 0.10) 0.24 
Multivariable -0.43 (-0.76, -0.10) 0.010  -0.11 (-0.35, 0.13) 0.38 
Combined* -0.32 (-0.67, 0.03) 0.072  -0.15 (-0.39, 0.10) 0.24 
Large non-cortical or cortical infarcts        
Univariable -1.02 (-1.35, -0.69) <0.001  -0.28 (-0.42, -0.13) <0.001 
Multivariable -0.66 (-0.97, -0.34) <0.001  -0.26 (-0.39, -0.12) <0.001 
Combined* -0.64 (-0.97, -0.31) <0.001  -0.26 (-0.40, -0.13) <0.001 
Microbleeds        
Univariable -0.39 (-0.81, 0.03) 0.07  0.03 (-0.09, 0.14) 0.66 
Multivariable -0.03 (-0.42, 0.36) 0.88  0.04 (-0.07, 0.14) 0.52 
Combined* 0.02 (-0.37, 0.41) 0.93  0.08 (-0.03, 0.19) 0.16 
White matter lesions        
Univariable -0.59 (-1.99, 0.81) 0.41  -0.38 ( -0.49, -0.28) <0.001 
Multivariable 0.14 (-1.20, 1.47) 0.84  -0.12 (-0.23, -0.01) 0.028 
Combined* 0.43 (-0.92, 1.78) 0.53  -0.06 (-0.18, 0.05) 0.29 
Fazekas scale ≥2        
Univariable -0.99 (-1.27, -0.72) <0.001     
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Multivariable -0.40 (-0.68, -0.11) 0.007     
Patients without a history of stroke or TIA 
Small non-cortical infarcts        
Univariable -0.85 (-1.24, -0.46) <0.001  -0.16 (-0.48, 0.16) 0.33 
Multivariable -0.44 (-0.82, -0.07) 0.021  -0.09 (-0.39, 0.21) 0.54 
Combined† -0.35 (-0.76, 0.05) 0.09  -0.05 (-0.36, 0.25) 0.74 
Large non-cortical or cortical infarcts        
Univariable -0.90 (-1.32, -0.48) <0.001  -0.21 (-0.42, -0.00) 0.06 
Multivariable -0.58 (-0.98, -0.18) 0.004  -0.19 (-0.39, 0.01) 0.06 
Combined† -0.53 (-0.94, -0.12) 0.012  -0.18 (-0.39, -0.02) 0.07 
Microbleeds        
Univariable -0.35 (-0.84, 0.13) 0.15  -0.01 (-0.17, 0.15) 0.93 
Multivariable 0.02 (-0.43, 0.48) 0.92  -0.01 (-0.16, 0.14) 0.94 
Combined† 0.06 (-0.40, 0.52) 0.81  0.03 (-0.12, 0.19) 0.66 
White matter lesions        
Univariable -0.58 (-2.05, 0.89) 0.44  -0.35 (-0.46, -0.24) <0.001 
Multivariable 0.14 (-1.26, 1.54) 0.85  -0.10 (-0.22, 0.02) 0.11 
Combined† 0.41 (-1.03, 1.85) 0.57  -0.04 (-0.17, 0.09) 0.57 
Fazekas scale ≥2        
Univariable -1.01 (-1.31, -0.72) <0.001     
Multivariable -0.46 (-0.77, -0.16) 0.003     
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MoCA: Montreal Cognitive Assessment; Results are from linear mixed effects models, taking into account the effect of study center. 
Vascular brain lesion volumes are centered on the mean natural-log transformed volumes. Models include, for each damage type, an 
indicator of the presence of the damage alongside the measurement of volume or, for microbleeds, count. Multivariable models are 
adjusted for age, sex, history of hypertension, smoking status, history of diabetes, body mass index, AF type, education level, oral 
anticoagulation (yes, no). Coefficients of all covariates are presented in the appendix, pages 6 and 9. The combined multivariable 
model includes all vascular brain lesion variables. Coefficients of all covariates from the combined model are presented in the 
appendix, pages 7 and 10. 
* The combined model included 1677 patients. 
† The combined model included 1344 patients. 
No. of patients with microbleeds=1682; No of patients with microbleeds without a history of stroke or TIA=1348 
